Blood tests are the gold standard for predicting disease progression. Unfortunately, blood tests may also be time consuming, expensive, and painful. What if your smartwatch could tell you when vital blood biomarkers change?
GPx is enhancing remote patient management by building a new class of biomarkers called Bloodless Blood Tests. Through our AI-powered Canary Prediction Engine, digital biomarkers collected from patient wearables and peripherals transform into an unparalleled window into patient blood biomarker status. With this data, physicians benefit from presymptomatic detection of critical patient condition changes, enabling timely treatment that avoids hospital readmissions.
General Prognostics (GPx) will be presenting at the upcoming #HRX2022’s Pitch Competition. We are excited about participating in HRX as a way to get feedback from individuals in the industry, form new partnerships, and grow awareness of our bloodless blood test technology. https://twitter.com/HRSonline/status/1542619490978078723
GPx is proud to announce that Jim Yearick has joined the company’s strategic advisory board. Jim is currently the Senior VP of sales and marketing at Endotronix, which is quickly improving the remote monitoring of heart failure patients. He brings over 30 years of medical device
General Prognostics (GPx) is excited to welcome Dr. Andrew Sauer to our medical advisory board. He guides the clinical strategy and is the PI for our US pilot launch and clinical study. Dr. Sauer has served as the founding Medical Director of the